Shares of Biopharmx Corp (NYSE:BPMX) have been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.
Brokerages have set a 1 year consensus price target of $3.38 for the company and are predicting that the company will post ($0.07) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Biopharmx Corp an industry rank of 159 out of 265 based on the ratings given to its competitors.
A number of equities analysts recently issued reports on BPMX shares. ValuEngine raised Biopharmx Corp from a “strong sell” rating to a “sell” rating in a report on Wednesday. Roth Capital set a $3.00 price target on Biopharmx Corp and gave the company a “buy” rating in a report on Thursday, February 9th.
ILLEGAL ACTIVITY NOTICE: “Zacks: Biopharmx Corp (BPMX) Given Average Recommendation of “Strong Buy” by Analysts” was first reported by sleekmoney and is the property of of sleekmoney. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://sleekmoney.com/zacks-biopharmx-corp-bpmx-given-average-recommendation-of-strong-buy-by-analysts/1856554.html.
Biopharmx Corp (NYSE:BPMX) traded up 0.5703% during mid-day trading on Friday, reaching $0.6349. 853,714 shares of the company were exchanged. The stock has a 50-day moving average of $0.64 and a 200 day moving average of $0.47. Biopharmx Corp has a 1-year low of $0.19 and a 1-year high of $1.22. The firm’s market capitalization is $42.99 million.
About Biopharmx Corp
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/zacks-biopharmx-corp-bpmx-given-average-recommendation-of-strong-buy-by-analysts/1856554.html
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.